Association of polymorphisms Gene CYP2C19 with endpoints of efficacy and safety of clopidogrel therapy And platelet aggregation in patients with acutecoronary syndrome study Protocol-Reference-Cited by-同舟云学术

Association of polymorphisms Gene CYP2C19 with endpoints of efficacy and safety of clopidogrel therapy And platelet aggregation in patients with acutecoronary syndrome study Protocol

Published:2017-03-29 Issue: Volume: Page:
ISSN:
Container-title:Topical issues of translational medicine
language:
Short-container-title:

Author:

Лифшиц Г.¹,Lifshic G.²,Зеленкская Е.¹,Zelenkskaya E.²,Сараева Н.³,Saraeva N.⁴,Горохова Анна³,Gorokhova Anna⁴,Апарцин Константин⁵⁶,Apartsin Konstantin⁷⁸

Affiliation:

1. Институт химической биологии и фундаментальной медицины СО РАН

2. Institut himicheskoy biologii i fundamental'noy mediciny SO RAN

3. Иркутская ордена «Знак Почёта» областная клиническая больница

4. Irkutskaya ordena «Znak Pocheta» oblastnaya klinicheskaya bol'nica

5. Иркутский научный центр хирургии и травматологии

6. Иркутский научный центр СО РАН

7. Irkutsk Scientific Center of Surgery and Traumatology

8. Irkutsk Scientific Center SB RAS

Abstract

Aim: to reveal the association of gene CYP2C19 polymorphisms and efficacy and safety endpoints of clopidogrel therapy in patients with acute coronary syndrome. Materials and methods. A total of 431 patients with acute coronary syndrome undergoing coronary stent placement was studied. CYP2C19 polymorphisms (*2, *3, *17) were evaluated, platelet aggregation with ADP and efficacy and safety for 30 days after coronary stent placement was studied. Results. Within the selected patients there was no significant association between carriage of at least one allele of the CYP2C19*2, and/or CYP2C19*3 and paradoxical response to clopidogrel. Significant association between carriage of allele CYP2C19*17 and the presence of bleeding was detected. The algorithm for selection of individual drug therapy for patients receiving clopidogrel therapy was developed. Conclusion. The results can be extremely important for decision-making about the strategy of dual antiplatelet therapy and the tactics of choice of drugs.

Publisher

INFRA-M Academic Publishing LLC.

Reference20 articles.

1. Aradi D., Storey R.F., Komócsi A., Trenk D. et al. On behalf of the Working Group on Thrombosis of the European Society of Cardiology Expert. Position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention // Eur. Heart J. – 2014. – Vol. 35 (4). – P. 209–215., Aradi D., Storey R.F., Komócsi A., Trenk D. et al. On behalf of the Working Group on Thrombosis of the European Society of Cardiology Expert. Position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention // Eur. Heart J. – 2014. – Vol. 35 (4). – P. 209–215.

2. Mega J.L., Simon T., Collet J.P., Anderson J.L. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis // JAMA. – 2010. – Vol. 304 (16). – P. 1821–1830., Mega J.L., Simon T., Collet J.P., Anderson J.L. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis // JAMA. – 2010. – Vol. 304 (16). – P. 1821–1830.

3. Harmsze A.M., van Werkum J.W., ten Berg J.M., Zwart B. et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case–control study // Eur. Heart J. – 2010. – Vol. 31 (24). – P. 3046., Harmsze A.M., van Werkum J.W., ten Berg J.M., Zwart B. et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case–control study // Eur. Heart J. – 2010. – Vol. 31 (24). – P. 3046.

4. Sibbing D., Stegherr J., Latz W., Koch W. et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention // Eur. Heart J. – 2009. – Vol. 30 (8). – P. 916–922., Sibbing D., Stegherr J., Latz W., Koch W. et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention // Eur. Heart J. – 2009. – Vol. 30 (8). – P. 916–922.

5. Clinical and translational science: principles of human research; 1st ed. / Ed. by D. Robertson, G.H. Williams. – 2009. – 579 p. 6. Лифшиц Г.И., Данилкина С.Т., Гуськова Е.В., Воронина Е.Н. Ассоциация генов, кодирующих белки гемостаза, с параметрами периферического гемостаза и предрасположенностью к атеротромбозам у пациентов с сердечно-сосудистыми заболеваниями // Кардиоваскулярная терапия и профилактика. – 2011. – № 4. – С. 90–96., Clinical and translational science: principles of human research; 1st ed. / Ed. by D. Robertson, G.H. Williams. – 2009. – 579 p. 6. Lifshic G.I., Danilkina S.T., Gus'kova E.V., Voronina E.N. Associaciya genov, kodiruyuschih belki gemostaza, s parametrami perifericheskogo gemostaza i predraspolozhennost'yu k aterotrombozam u pacientov s serdechno-sosudistymi zabolevaniyami // Kardiovaskulyarnaya terapiya i profilaktika. – 2011. – № 4. – S. 90–96.